Karolinska Development company Aprea Therapeutics Announces Research Collaboration with Memorial Sloan Kettering Cancer Center
(WorldNews Sweden)

Press Releases Karolinska Development company Aprea Therapeutics Announces Research Collaboration with Memorial Sloan Kettering Cancer Center STOCKHOLM - March 22, 2017. Karolinska Development`s portfolio company Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumor suppressor protein p53 by APR-246. Details from the Aprea Therapeutics press release follow: The goal of the collaboration is to evaluate and characterize preclinical efficacy of APR-246 in combination...